Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | PTPRZ1 | P23471 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648537 | 0.82 | AGXT (0.39) | IDO1 | |
| SCHEMBL22708283 | 0.82 | SLC6A4 (0.44) | SLC6A4 | |
| SCHEMBL19638101 | 0.76 | AGXT (0.41) | IDO1 | |
| SCHEMBL2452819 | 0.74 | ESR1 (0.54) | SLC6A4HSD17B10ARIDO1 | |
| SCHEMBL7935343 | 0.74 | AGXT (0.54) | IDO1 | |
| SCHEMBL12314673 | 0.73 | IDO1 (0.59) | KDM4EARIDO1 | |
| SCHEMBL21013186 | 0.73 | SLC6A4 (0.44) | SLC6A4PTPRZ1KDM4E | |
| SCHEMBL18773888 | 0.72 | AGXT (0.32) | IDO1 | |
| SCHEMBL22385098 | 0.72 | AGXT (0.32) | IDO1 | |
| SCHEMBL1691492 | 0.72 | APP (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270874-A1 | ANTIBODY DRUG CONJUGATE LOADED WITH BINARY TOXINS AND ITS APPLICATION | MABPLEX INTERNATIONAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230270874-A1 | ANTIBODY DRUG CONJUGATE LOADED WITH BINARY TOXINS AND ITS APPLICATION | MABPLEX INTERNATIONAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270874-A1 | ANTIBODY DRUG CONJUGATE LOADED WITH BINARY TOXINS AND ITS APPLICATION | MMAB, TNFSF10, CD47 | SLC6A4 3168/4885PTPRZ1 1801/4885KDM4E 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.